Search | Socid Friendly

Subhayan Mayra eine Datei hinzugefügt Health
2026-04-15 11:48:15

Brigatinib API Market Growing at 8.1% CAGR Through 2034 Globally
According to a new report from Intel Market Research, the global Brigatinib API market was valued at USD 42.5 million in 2025 and is projected to reach USD 89.7 million by 2034, growing at a robust CAGR of 8.1% during the forecast period (2026–2034). This growth is propelled by the increasing global incidence of non-small cell lung cancer, particularly ALK-positive cases among...

0 Kommentare 0 Anteile 811 Ansichten

Please log in to like, share and comment!
Subhayan Mayra eine Datei hinzugefügt Other
2026-04-22 10:24:52

Crizotinib Drugs Market Growing at 6.7% CAGR Through 2034
According to a new report from Intel Market Research, the global Crizotinib Drugs market was valued at USD 582.4 million in 2025 and is projected to reach USD 1,043.7 million by 2034, growing at a CAGR of 6.7% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of lung cancer, increasing adoption of molecular diagnostic testing for genetic...

0 Kommentare 0 Anteile 139 Ansichten

Please log in to like, share and comment!
Subhayan Mayra eine Datei hinzugefügt Other
2026-04-20 11:20:27

Global Multi-target MET TKIs Market Growing at 7.6% CAGR Through 2034
According to a new report from Intel Market Research, the global Multi-target MET TKIs market was valued at USD 1.52 billion in 2025 and is projected to reach USD 3.18 billion by 2034, growing at a CAGR of 7.6% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of non-small cell lung cancer and medullary thyroid cancer, precision oncology...

0 Kommentare 0 Anteile 245 Ansichten

Please log in to like, share and comment!
Subhayan Mayra eine Datei hinzugefügt Other
2026-04-13 12:28:25

Global Selpercatinib Capsules Market Growing at 7.8% CAGR Through 2034
According to a new report from Intel Market Research, the global Selpercatinib Capsules market was valued at USD 420 million in 2025 and is projected to reach USD 820 million by 2034, growing at a CAGR of 7.8% during the forecast period (2026–2034). This growth is propelled by the increasing prevalence of RET-altered cancers, growing adoption of biomarker-driven therapies, and...

0 Kommentare 0 Anteile 748 Ansichten

Please log in to like, share and comment!